VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

November 22, 2015

"Thyroid cancer patients are in serious need of targeted treatments that effectively manage their disease," said Keith Bible, M.D., Ph.D., the lead investigator of the study from the Mayo Clinic. "While radioactive iodine can be an effective treatment for metastatic thyroid cancer, not all thyroid cancers concentrate iodine and some patients become resistant to it. Those patients are left with few treatment options. VB-111's unique mechanism of action shows exciting potential to treat this population of patients with thyroid cancer."

VB-111 in GBM

This Phase 1/2 prospective, open-label, single-dose, multi-center study will enroll patients with relapsed GBM. Researchers will evaluate its effect, as measured by six months of progression-free survival. The study will also examine the bio-distribution of VB-111 in the body. Finally, the study will assess and characterize VB-111's safety and tolerability.

"GBM is an extremely aggressive form of brain cancer and it is exceedingly hard to treat with currently available therapies, which include surgery, radiation and chemotherapy," said James Vredenburgh, M.D., the lead investigator of the study from Duke University Medical Center. "These therapies are palliative in nature, not curative, leaving patients with few treatment options. We are hopeful that the positive Phase 1/2 results we have seen with VB-111 will be validated by this study."

Source: VBL Therapeutics